Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
  • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/906—Zingiberaceae (Ginger family)
  • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
  • A61K2236/30—Extraction of the material
  • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
  • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
  • A61K47/544—Phospholipids

Definitions

• the present invention relates to novel phospholipids complexes of curcumin or extracts containing it having improved bioavailability.
• Curcumin [1,7-bis(4-hydroxyl-3-methoxyphenyl)-1,6-heptadiene-3,5-dione], is the major constituent of the spice turmeric extracted from the root of Curcuma longa Linn.
• Curcumin is a polyphenol that has powerful antioxidant and inhibits the expression of the enzyme cyclooxygenase 2 (Cox 2) at least in part via interference with activation of the transcription factor NFkB [2, 14].
• Cox 2 cyclooxygenase 2
• curcumin inhibits the growth of cancer cells with an IC 50 value of 20-75 ⁇ M [6, 16].
• curcumin has been shown to prevent cancer in the colon, skin, stomach, duodenum, soft palate, tongue, sebaceous glands and breast [9, 10, 15].
• curcumin could be considered a promising efficacious and safe cancer chemopreventive agents [18].
• clinical pilot studies have associated curcumin consumption with regression of pre-malignant lesions of bladder, soft palate stomach, cervix and skin [1, 11].
• Complex compounds of vegetable extracts or of purified components thereof with natural, synthetic or semi-synthetic phospholipids have been disclosed, e.g., in EP 209 038, EP 275 005, EP 283 713, EP 1 035 859 and EP 1 140 115. Said complexes improve the plasma bioavailability of the extract or purified component, thanks to their lipophilicity.
• EP 1 140 115 generically mentions ethanol among the various solvents that can be used of the preparation of said complexes, but does not provide preparation examples which make use of ethanol as the solvent.
• the complexes disclosed are phospholipid complexes of proanthocyanidin A2, which are quite different in the chemical structure with respect to the phospholipids complexes of curcumin of the present invention.
• the present invention relates to novel phospholipids complexes of curcumin having improved bioavailability.
• phospholipids of either vegetable or synthetic origin can be used, particularly preferred are soy phospholipids, such as phosphatidyl choline, phosphatidyl serine, phosphatidyl ethanolamine.
• the complexes are prepared by adding the phospholipid to curcumin dissolved in a protic solvent, more particularly adding the phospholipid to the ethanol solution of the hydroalcoholic extract of turmeric rhizomes, under reflux and with stirring.
• the resulting suspension is concentrated under reduced pressure to a residue which is dried in oven.
• the ratio of phospholipids to curcumin is in the range from 10 to 1 w/w, a more preferable mole ratio being 5:1 w/w.
• the present invention also relates to pharmaceutical compositions containing as the active principle one of the phospholipids complexes of curcumin according to the invention, in admixture with a suitable pharmaceutical carrier.
• the present invention further relates to the use of the phospholipids complexes of curcumin of the invention for the preparation of medicaments having chemopreventive action.
• Ground dry turmeric rhizomes 1000 g were extracted with ethanol-water 9:1 mixture (6680 ml). The resulting hydroalcoholic solution was concentrated under reduced pressure and drying was completed in oven at 60° C. under vacuum to yield 69.3 g of an orange paste having a curcumin content of 17.4% w/w and a total curcuminoid content of 29.2% w/w.
• Ground dry turmeric rhizomes 1000 g were defatted with hexane (2500 ml) before being extracted with ethanol-water 95:5 mixture (7500 ml). Curcuminoids were then crystallized by slowly adding hexane (500 ml) to the hydroalcoholic solution and allowing the resulting mixture to stand for 24 hours. A microcrystalline orange solid was filtered and dried at 60° C. under vacuum to yield 36.7 g of extract having a curcumin content of 71.74% and a total curcuminoid content of 93.8% w/w.
• the 1 H-NMR spectrum of the complex in CDCl 3 shows the main signals of the phospholipids, typical of complexed phospholipids.
• the 1 H-NMR spectrum of the complex in DMSO-d 6 which is a solvent preventing the aggregation of the complex, shows the signals of the free starting extract as well as those of the phospholipids.
• the signal of 31 P in CDCl 3 is at 1.06 ppm and is 35.3 Hz wide, which is typical of complexed phospholipids.
• the complex is destroyed in DMSO-d 6 as confirmed by the signal of 31 P at 0.12 ppm with 3.80 Hz width typical of the free phospholipid.
• Tests were carried out to compare curcumin bioavailability afforded by the phospholipid complexes of the invention and by the extract containing uncomplexed curcumin.
• Rats were killed at 15, 30, 60 and 120 min. Whole blood was collected into heparinized tubes, centrifuged immediately at 7000 ⁇ g for 15 min, plasma was then decanted and stored at ⁇ 80° C. until analysis.
• curcumin and metabolites were verified by negative ion electrospray liquid chromatography/tandem mass spectrometry as previously described (4, 5, 7).
• the improved bioavailability of phospholipid complex of curcumin increases the potential scope of medical applications for curcumin as a chemopreventive agent.

Applications Claiming Priority (4)

Related Parent Applications (1)

Related Child Applications (1)

Publications (2)

Family

ID=36677274

Family Applications (2)

Family Applications After (1)

Country Status (17)

Families Citing this family (46)

Citations (1)

Family Cites Families (6)

• 2006
  • 2006-03-09 EP EP06004820A patent/EP1837030A1/en not_active Withdrawn
• 2007
  • 2007-02-21 JP JP2008557619A patent/JP5448462B2/ja active Active
  • 2007-02-21 EP EP07703532.7A patent/EP1991244B1/en active Active
  • 2007-02-21 SI SI200732132T patent/SI1991244T1/sl unknown
  • 2007-02-21 CA CA2644017A patent/CA2644017C/en active Active
  • 2007-02-21 HU HUE07703532A patent/HUE046597T2/hu unknown
  • 2007-02-21 CN CNA2007800082936A patent/CN101400360A/zh active Pending
  • 2007-02-21 PT PT77035327T patent/PT1991244T/pt unknown
  • 2007-02-21 ES ES07703532T patent/ES2757580T3/es active Active
  • 2007-02-21 WO PCT/EP2007/001487 patent/WO2007101551A2/en active Application Filing
  • 2007-02-21 US US12/281,994 patent/US10603329B2/en active Active
  • 2007-02-21 PL PL07703532T patent/PL1991244T3/pl unknown
  • 2007-02-21 RU RU2008136189/15A patent/RU2450818C2/ru active
  • 2007-02-21 KR KR1020087021905A patent/KR101423269B1/ko active IP Right Grant
  • 2007-02-21 DK DK07703532T patent/DK1991244T3/da active
  • 2007-02-21 AU AU2007222667A patent/AU2007222667B2/en active Active
• 2008
  • 2008-09-08 NO NO20083850A patent/NO344242B1/no unknown
  • 2008-09-08 IL IL193966A patent/IL193966A/en active IP Right Grant
• 2019
  • 2019-02-13 US US16/274,623 patent/US20190175628A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events